FY2022 · ended Sep 30, 2022 · Revenue $90,000, +0.0% YoY · Filed Dec 29, 2023
Citius Pharmaceuticals, Inc. (CTXR) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $17.0 million in cash and investments and $300.8 million in total debt.
Revenue
$90,000
+0.0% vs prior year
Net income (TTM)
$-58.17M
-38.2% vs year-ago TTM
Operating cash flow (TTM)
$-34.87M
-69.4% vs year-ago TTM
Free cash flow
$-24.26M
-43.3% vs prior year
EPS (TTM)
$-2.13
+55.6% vs year-ago TTM
Dividend per share
$0.60
Shares outstanding
20.76M
+168.7% vs prior year
Net cash
$-283.76M
as of Jun 30, 2026
Operating margin
-37017.8%
FY 2022
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CTXR (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- NV
- Headquarters
- Cranford, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1506251
- Former names
- Trail One, Inc. (until Sep 18, 2014); TrailOne, Inc. (until Jan 21, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Sep 30, 2025 |
FY 2024 Sep 30, 2024 |
FY 2023 Sep 30, 2023 |
FY 2022 Sep 30, 2022 |
FY 2021 Sep 30, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $90,000 | $90,000 |
| Operating income | -$38.5M | -$42.0M | -$36.7M | -$33.3M | -$23.5M |
| Net income | -$39.7M | -$39.4M | -$32.5M | -$33.6M | -$23.1M |
| Diluted EPS | -$3.38 | -$5.97 | — | -$0.23 | — |
| Operating cash flow | -$26.6M | -$28.2M | -$29.1M | -$28.4M | -$24.3M |
| Free cash flow | — | — | — | — | -$24.3M |
| Total assets | $130.9M | $116.7M | $103.6M | $114.0M | $142.4M |
| Total liabilities | $53.4M | $42.5M | $12.2M | $10.6M | $9.6M |
| Stockholders' equity | $67.6M | $70.1M | $90.8M | $102.8M | $132.2M |
| Cash and investments | $4.3M | $3.3M | $26.5M | $41.7M | $70.1M |
| Total debt | $300.8M | $262,865 | $481,245 | $678,234 | $855,471 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Listing notice
|
Aug 21, 2026 | Aug 17, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2026 | Aug 14, 2026 |
| 8-K |
Current report
Other events
|
Aug 5, 2026 | Aug 5, 2026 |
All 638 Citius Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.